These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 27094684)

  • 1. Genome-wide profiles of methylation, microRNAs, and gene expression in chemoresistant breast cancer.
    He DX; Gu F; Gao F; Hao JJ; Gong D; Gu XT; Mao AQ; Jin J; Fu L; Ma X
    Sci Rep; 2016 Apr; 6():24706. PubMed ID: 27094684
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Methylation-regulated miR-149 modulates chemoresistance by targeting GlcNAc N-deacetylase/N-sulfotransferase-1 in human breast cancer.
    He DX; Gu XT; Li YR; Jiang L; Jin J; Ma X
    FEBS J; 2014 Oct; 281(20):4718-30. PubMed ID: 25156775
    [TBL] [Abstract][Full Text] [Related]  

  • 3. miRNA expression patterns in chemoresistant breast cancer tissues.
    Lv J; Xia K; Xu P; Sun E; Ma J; Gao S; Zhou Q; Zhang M; Wang F; Chen F; Zhou P; Fu Z; Xie H
    Biomed Pharmacother; 2014 Oct; 68(8):935-42. PubMed ID: 25451164
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification and characterization of microRNAs expressed in human breast cancer chemo-resistant MCF-7/Adr cells by Solexa deep-sequencing technology.
    Xu P; Wang L; Huang L; Li W; Lv S; Lv M; Ma J; Zhou Q; Wu X; Fu Z; Lu C; Yin H
    Biomed Pharmacother; 2015 Oct; 75():173-8. PubMed ID: 26293775
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bioinformatic identification of chemoresistance-associated microRNAs in breast cancer based on microarray data.
    Wang YW; Zhang W; Ma R
    Oncol Rep; 2018 Mar; 39(3):1003-1010. PubMed ID: 29328395
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Integration of microRNA signatures of distinct mammary epithelial cell types with their gene expression and epigenetic portraits.
    Pal B; Chen Y; Bert A; Hu Y; Sheridan JM; Beck T; Shi W; Satterley K; Jamieson P; Goodall GJ; Lindeman GJ; Smyth GK; Visvader JE
    Breast Cancer Res; 2015 Jun; 17(1):85. PubMed ID: 26080807
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A methylation-based regulatory network for microRNA 320a in chemoresistant breast cancer.
    He DX; Gu XT; Jiang L; Jin J; Ma X
    Mol Pharmacol; 2014 Nov; 86(5):536-47. PubMed ID: 25159093
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genes suppressed by DNA methylation in non-small cell lung cancer reveal the epigenetics of epithelial-mesenchymal transition.
    Lin SH; Wang J; Saintigny P; Wu CC; Giri U; Zhang J; Menju T; Diao L; Byers L; Weinstein JN; Coombes KR; Girard L; Komaki R; Wistuba II; Date H; Minna JD; Heymach JV
    BMC Genomics; 2014 Dec; 15(1):1079. PubMed ID: 25486910
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Methylation of Notch3 modulates chemoresistance via P-glycoprotein.
    Gu X; Lu Y; He D; Lu C; Jin J; Lu X; Ma X
    Eur J Pharmacol; 2016 Dec; 792():7-14. PubMed ID: 27780727
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MicroRNA-125b upregulation confers aromatase inhibitor resistance and is a novel marker of poor prognosis in breast cancer.
    Vilquin P; Donini CF; Villedieu M; Grisard E; Corbo L; Bachelot T; Vendrell JA; Cohen PA
    Breast Cancer Res; 2015 Jan; 17(1):13. PubMed ID: 25633049
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of the miRNA-mRNA-lncRNA networks in ER+ and ER- breast cancer cell lines.
    Wu Q; Guo L; Jiang F; Li L; Li Z; Chen F
    J Cell Mol Med; 2015 Dec; 19(12):2874-87. PubMed ID: 26416600
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systematic analysis of gene expression pattern in has-miR-760 overexpressed resistance of the MCF-7 human breast cancer cell to doxorubicin.
    Lv J; Fu Z; Shi M; Xia K; Ji C; Xu P; Lv M; Pan B; Dai L; Xie H
    Biomed Pharmacother; 2015 Feb; 69():162-9. PubMed ID: 25661353
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reconstruction of temporal activity of microRNAs from gene expression data in breast cancer cell line.
    Jayavelu ND; Bar N
    BMC Genomics; 2015 Dec; 16():1077. PubMed ID: 26763900
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MicroRNA expression profiles of drug-resistance breast cancer cells and their exosomes.
    Zhong S; Chen X; Wang D; Zhang X; Shen H; Yang S; Lv M; Tang J; Zhao J
    Oncotarget; 2016 Apr; 7(15):19601-9. PubMed ID: 26910922
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MiR-489 regulates chemoresistance in breast cancer via epithelial mesenchymal transition pathway.
    Jiang L; He D; Yang D; Chen Z; Pan Q; Mao A; Cai Y; Li X; Xing H; Shi M; Chen Y; Bruce IC; Wang T; Jin L; Qi X; Hua D; Jin J; Ma X
    FEBS Lett; 2014 May; 588(11):2009-15. PubMed ID: 24786471
    [TBL] [Abstract][Full Text] [Related]  

  • 16. miR-218 targets survivin and regulates resistance to chemotherapeutics in breast cancer.
    Hu Y; Xu K; Yagüe E
    Breast Cancer Res Treat; 2015 Jun; 151(2):269-80. PubMed ID: 25900794
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MicroRNA Profile in Response to Doxorubicin Treatment in Breast Cancer.
    Tormo E; Pineda B; Serna E; Guijarro A; Ribas G; Fores J; Chirivella E; Climent J; Lluch A; Eroles P
    J Cell Biochem; 2015 Sep; 116(9):2061-73. PubMed ID: 25802200
    [TBL] [Abstract][Full Text] [Related]  

  • 18. miR-381 inhibited breast cancer cells proliferation, epithelial-to-mesenchymal transition and metastasis by targeting CXCR4.
    Xue Y; Xu W; Zhao W; Wang W; Zhang D; Wu P
    Biomed Pharmacother; 2017 Feb; 86():426-433. PubMed ID: 28012397
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dual regulation by microRNA-200b-3p and microRNA-200b-5p in the inhibition of epithelial-to-mesenchymal transition in triple-negative breast cancer.
    Rhodes LV; Martin EC; Segar HC; Miller DF; Buechlein A; Rusch DB; Nephew KP; Burow ME; Collins-Burow BM
    Oncotarget; 2015 Jun; 6(18):16638-52. PubMed ID: 26062653
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MicroRNA-21 links epithelial-to-mesenchymal transition and inflammatory signals to confer resistance to neoadjuvant trastuzumab and chemotherapy in HER2-positive breast cancer patients.
    De Mattos-Arruda L; Bottai G; Nuciforo PG; Di Tommaso L; Giovannetti E; Peg V; Losurdo A; Pérez-Garcia J; Masci G; Corsi F; Cortés J; Seoane J; Calin GA; Santarpia L
    Oncotarget; 2015 Nov; 6(35):37269-80. PubMed ID: 26452030
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.